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Chondroid tumors comprise a heterogenous group of benign to overt malignant neoplasms, which may
be difﬁcult to differentiate from one another by histological examination. A group of 43 such tumors
was stained with nine relevant antibodies in an attempt to ﬁnd consistent marker proﬁle(s) for the dif-
ferent subgroups. Archival material from three extraskeletal myxoid chondrosarcomas, ﬁve chordo-
mas, ﬁve chondromyxoid ﬁbromas, ﬁve chondroblastomas and 25 chondrosarcomas was stained with
antibodies against osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-
kit) andYKL-40. All 25chondrosarcomas showed apositive staining reaction for D2-40,none for actin
and CD117, and a partial reactivity for bcl-2 (36%). Chondroblastomas (5/5) and chondromyxoid ﬁ-
bromas (2/5) were the only tumors with a positive reaction for actin, and all chondroblastomas (n=5)
and extraskeletal myxoid chondrosarcomas (n=3) were positive for bcl-2. In contrast to all other tu-
mors, two of three extraskeletal myxoid chondrosarcomas were also positive for CD17 and negative for
osteonectin, cox-2, mdm-2 and actin. All ﬁve chordomas were negative for D2-40 and positive for
mdm-2 and YKL-40. The diagnosis of chondrosarcoma may be aided by its positivity for D2-40 and
YKL-40 and its lack of reactivity for actin and CD117. This should be seen in the light of no reaction
for D2-40 in chordomas and a corresponding lack of reaction for osteonectin, cox-2, mdm-2 and actin
in extraskeletal myxoid chondrosarcomas. A convincing immunoreactivity for calponin and/or actin in
chondromyxoid ﬁbromas and chondroblastomas may also be helpful in differentiating these tumors
from chondrosarcomas.
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Chondroid tumors are rare, the most common
subtype being the chondrosarcoma, with an in-
cidence of about two per million per year (1).
Chondromyxoid ﬁbromas, chondroblastomas and
chordomas are less common, but they are difﬁ-
cult to differentiate from chondrosarcomas
because of overlapping histological morphology
and limited experience in diagnosing these
rare tumors. In contrast to the malignant
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518chondrosarcoma, chondromyxoid ﬁbroma and
chondroblastoma are benign, generally indolent
lesions, but they may recur and threaten the func-
tion of a neighboring joint. The behavior of chor-
domas, on the other hand, is impossible to predict
from histology alone. Some tend to recur locally,
and some are frankly malignant and metastasize.
An exact subclassiﬁcation of chondroid tu-
mors by means of markers that reveal the dif-
ferent molecular genetic characteristics is of
importance for future therapeutic treatments.
Chondrosarcomas and chordomas are resistant
to both chemotherapy and radiation, and the
mainstay of treatment today is radical surgery.
Finding an antibody panel against markers,
which could be of help in the diagnosis of these
rare chondroid tumors, thus differentiating be-
nign from potentially malignant subtype, was
one goal of this study. The other was ﬁnding
marker(s) of future therapeutic value. We in-
cluded D2-40 (podoplanin), a known marker of
chondrosarcoma (2), bcl-2, an inhibitor of
apoptosis and effector of the Indian hedgehog/
parathyroid hormone-like hormone pathway,
and COX-2, a mediator of angiogenesis, both
molecular markers of possible therapeutic tar-
geting [for a review, see (3)], YKL-40, a ‘high
activity’ marker (4, 5), osteonectin (SPARC or
BM-40), a known marker of osteosarcomas,
chondrocytes and other mesenchymal cells (6),
the muscle/myoﬁbroblastic markers actin (7)
and calponin (8), mdm-2, a marker of lipo-
sarcomas (9) and CD117 (c-kit), a marker of
gastrointestinal stromal tumors with mutations
in c-kit and PDGFRa (10).
The markers were applied by immunohisto-
chemistry to a series of 43 chondroid tumors
of the categories mentioned above. For com-
parison, three extraskeletal myxoid chon-
drosarcomas were included, although these
tumors, in spite of their name and histologic re-
semblance to myxoid chondrosarcomas (grade
II) of bone origin, are considered non-chondroid
and have been reclassiﬁed as ‘tumors of un-
certain differentiation’ in the recent 2002 WHO
classiﬁcation (4).
MATERIALS AND METHODS
From the archives of the Department of Pathology at
Rigshospitalet, we retrieved slides and parafﬁn blocks
from and conﬁrmed the diagnosis of three extra-
skeletal myxoid chondrosarcomas, ﬁve chordomas,
ﬁve chondromyxoid ﬁbromas, ﬁve chondroblastomas
and 25 chondrosarcomas of different grades. Because
of severe problems with inter-observer variation in
the grading of the latter, it was decided to re-use ma-
terial from a previous study, in which grade had been
established through consensus among three experi-
enced observers (11).
To secure adherence of the chondroid tissue to the
slides, these were baked dry in an oven at 601C for
40min and then kept at 371C for 65h. The procedure
did not affect immunohistochemical staining results,
with the exception of the marker bcl-2, which is heat
labile. Dilution of this antibody was consequently
adjusted to 1:50 as opposed to 1:400, which is used in
daily routine.
The antibodies and their dilutions are listed in
Table 1. Heat-induced epitope retrieval was per-
formed in a microwave oven (15min at 981C in Tris-
EGTA buffer, pH 9). The slides were incubated for
1h at room temperature and routinely processed with
the reactions visualized using Dako’s EnVision kit
with DAB chromogen on a Dako TechMate staining
machine (Glostrup, Denmark).
Staining for YKL-40 was carried out manually,
because the procedure differed from that above: anti-
gen retrieval was performed in a conventional oven
(18h at 601C in Tris-EGTA buffer, pH 9). After per-
oxidase blocking, the sections were pre-incubated
with 5% puriﬁed bovine serum albumin (BSA) (Dade
Behring, Marburg, Germany) for 10min, and then
incubated with primary mouse monoclonal antibody
anti-human YKL-40 (IgG2b clone 201 lot no. F9,
3.8mg/ml, directed against epitopes in amino acid
positions 210–220; supplied by Paul A. Price, UCSD,
La Jolla, CA, USA) diluted in 1% BSA for 1h. The
reaction was visualized with Dako’s EnVision System
as above. Apart from the antigen retrieval, all steps
were performed at room temperature in a humidity
chamber to avoid drying out of the sections.
Staining results were scored semi-quantitatively
(0=no staining, 1=weak staining, and 11=
moderate to intense staining), and the staining pattern
was noted (focal/diffuse/varying in intensity). For
bcl-2 (cytoplasmic reaction), cox-2 (cytoplasmic reac-
tion) and mdm-2 (nuclear reaction), a percentage was
estimated by counting 100 cells, if possible.
RESULTS
The staining results are summarized in Table 2
Extraskeletal myxoid chondrosarcomas (three
cases). – Two cases were well differentiated
(classical). Both were positive for CD117
(Fig. 1L) and to some degree also for bcl-2. They
were only weakly positive for D2-40. The other
markers, including YKL-40 (Fig. 1K), were
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pleomorphism and necrosis: this tumor was ne-
gative for CD117, but showed focal positivity
for calponin and D2-40 and a variable, weak to
moderate staining for YKL-40. A very weak cy-
toplasmic reaction for cox-2 was seen in some of
the tumor cells bordering foci of necrosis, pre-
sumably non-speciﬁc.
Chordomas (ﬁve cases). – Two cases exhibited a
weak positivity for osteonectin, mainly periph-
erally in the tumor nodules. No reaction was
seen for bcl-2, actin, D2-40 (Fig. 1H) or CD117,
and only one case exhibited a weak positivity for
calponin. Two cases were positive for cox-2
(about 10% and 40% of tumor cells, respec-
tively; Fig. 1D). All showed some reactivity for
mdm-2 (4–45% of nuclei) (Fig. 1G) and YKL-40,
which, however, was highly variable. One case,
with only 4% mdm-2-positive cells and a weak
(1) reaction for YKL-40, appeared morpholo-
gically to have been suboptimally ﬁxed.
Chondromyxoid ﬁbromas (ﬁve cases). – The
chondroid and myxoid areas were negative for
osteonectin, except in one case, where about
25% of the tumor cells were positive (Fig. 1B).
Otherwise, areas with reactive bone formation
and scattered cells in the spindled areas ex-
hibited some positivity (possibly myoﬁbro-
blasts). Cox-2 stained about 50% of the
myxochondroid tumor cells in three cases,
whereas two were negative. Bcl-2 exhibited a
generally weak and focal positivity in three cases
(5–10% of tumor cells), while two cases were
more strongly positive (20–50% of tumor cells).
Of the myogenic markers, actin was focally po-
sitive in only two cases and calponin was
strongly positive in one (Fig. 1F). Mdm-2 ex-
hibited a varying nuclear positivity in three cases
(from 5% to 35%), and the same three cases
were also positive for D2-40. CD117 was nega-
tive, and YKL-40 was positive in the chondroid
areas in all cases, albeit with varying intensity.
Chondroblastomas (ﬁve cases). – Osteonectin
was invariably negative in the cellular areas and
centrally in the obvious chondroid areas, but in
two cases positivity was encountered in myxoid
spindle cell areas and peripherally in the chon-
droid. Cox-2 was positive in all cases (varying
between 5% and 50% of tumor cells). Also, all
cases exhibited at least focal positivity for actin
(Fig. 1E), and three for calponin. No signiﬁcant
reaction was seen for mdm-2: only two cases ex-
hibited a weak positivity in 1–2% of tumor cells.
No reaction was seen for bcl-2 and CD117.
D2-40 was positive in all cases but with varying
intensity. YKL-40 was negative in two cases and
positive in three – only in the chondroid areas.
Chondrosarcomas (25 cases). – A variable and
often focal positivity was seen for osteonectin –
in some cases most intense in the periphery of
the tumor nodules (Fig. 1A). Bcl-2 exhibited
variable positivity in nine cases, six of them
being grade II (Fig. 1C). Cox-2 was negative in
12 cases, while 13 showed a varying positivity,
ranging from 4% to 50%, with a considerable
intra-tumoral variation. Actin was negative in
all cases. Calponin was also negative, apart from
four cases exhibiting a doubtful, weak, focal
positivity. Eight cases exhibited nuclear positiv-
ity for mdm-2, varying between 2 and 40% of
nuclei. A cytoplasmic reaction was present in a
larger proportion of tumor cells in the same
cases, and one case showed only cytoplasmic
staining (not regarded as positive). A generally
moderate or strong reaction was seen for both
Table 1. List of antibodies
Name Clone Supplier Dilution Control tissue
Osteonectin/SPARC ON1-1 Zymed 1:6000 Osteosarcoma
BCL2 oncoprotein 124 Dako 1:50 Lymph node
Cox-2 SP21 Neomarkers 1:800 Intestine
Actin (smooth muscle) 1A4 Dako 1:400 Intestine
Calponin CALP Dako 1:300 Intestine
Mdm-2 1F2 Zymed 1:50 Liposarcoma
D2-40, podoplanin, Aggrus D2-40 Dako 1:50 Intestine
CD117, c-kit Rabbit polyclonal Dako 1:200 Intestine
YKL-40 209F9 see ‘‘Material and methods’’ 1:100 Fetal cartilage
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was seen for CD117.
DISCUSSION
The diagnosis of chondroid tumors and their
mimics can be difﬁcult to make outside large re-
ferral centers, and even here, where it is usually
accomplished by a combination of microscopy
and clinical ﬁndings (including image diag-
nostics), difﬁculties may occur if the material is
sparse, poorly preserved or traumatized. The
results of this study are therefore encouraging,
as some of the antibodies appear to be of assis-
tance in subclassiﬁcation of the tumors, and
some of the markers may even point to new
therapeutic strategies in the future.
The most signiﬁcant ﬁnding was the universal
immunoreactivity of the 25 chondrosarcomas
for both D2-40 and YKL-40. Both of these
failed to show any consistent patterns for the
other tumors, and as D2-40 was completely ne-
gative in all our chordomas – an observation
conﬁrmed by Huse et al. (12) and to some extent
also Oakley et al. (2) – it may be of help in distin-
guishing these tumors from chondrosarcomas.
The transcription factor brachyury, a regulator
of notochordal development, has recently pro-
ven highly speciﬁc as a positive marker of chor-
domas as opposed to other chondroid tumors
(2, 13), and these two markers are likely to ef-
fectively supplement each other immunohisto-
chemically in the distinction between chordomas
and chondrosarcomas.
D2-40, an antibody with several names
(podoplanin, Aggrus, M2A and hT1a-2) is di-
rected against a transmembrane glycoprotein,
and its main use in diagnostic pathology is as a
marker of lymphatic endothelium, germinal cell
tumors and mesotheliomas, but it also reacts
with myoﬁbroblasts, chondrocytes and osteo-
cytes (2, 14). The antibody may also function as
a prognostic marker. Experimental evidence has
shown that over-expression promotes metas-
tasis, which may lead to a more aggressive ther-
apeutic intervention (15).
The essential driving force for cartilage differ-
entiation is the Indian hedgehog/parathyroid
hormone-like hormone pathway. Studies have
suggested that the transition from osteochon-
droma to chondrosarcoma is characterized by
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hormone-like hormone signalling, and that bcl-
2, an effector of this, is expressed in peripheral
and high-grade central chondrosarcomas [for a
review, see (3)]. Our results regarding bcl-2
should probably be interpreted with caution.
The antigen is heat labile and even though the
concentration of the antibody had to be in-
creased the lymphocytic reaction was in some
cases extremely weak, presumably due to over-
decalciﬁcation. However, in spite of these prac-
tical shortcomings, we found positivity in two of
10 grade I, six of 12 grade II and two of three
grade III chondrosarcomas, in accordance with
the ﬁndings of Bove ´ e et al. (16) and Hameetman
et al. (17), that up-regulation of bcl-2 is an early
event in some (peripheral) tumors and a late oc-
currence in others (central ones). Unfortunately,
it has not been possible for us to classify the tu-
mors reliably as either peripheral or central in
this retrospective material. Bcl-2 reactivity was
also seen in the chondromyxoid ﬁbromas while
Fig. 1. (A) Osteonectin, chondrosarcoma grade III. (B) Osteonectin, chondromyxoid ﬁbroma. (C) Bcl-2, chon-
drosarcoma grade II. (D) Cox-2, chordoma. (E) Actin, chondroblastoma. (F) Calponin, the single chon-
dromyxoid ﬁbroma with a 11 reaction. (G) Mdm-2, chordoma. (H) D2-40 (podoplanin), advancing edge of
chordoma with soft tissue invasion. The only positivity is seen in compressed lymph vessels. (I) D2-40 (podo-
planin), chondrosarcoma grade II. (J) YKL-40, chondrosarcoma grade II. (K) YKL-40, ESMC. Note staining of
the contents in the blood vessel. (L) CD117, ESMC. All magniﬁcations originally 200.
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different paths of tumorogenesis for these two
entities despite their superﬁcial resemblance.
Extraskeletal myxoid chondrosarcomas are not
known to have a diagnostic immunohisto-
chemical proﬁle (18), but our two classic cases
distinguished themselves from the other entities
in being positive for CD117 and at least focally
for bcl-2, while they were mainly negative for
YKL-40 (one case exhibited a weak, granular
reaction). CD117 (c-kit) positivity has been re-
ported previously. Hornick and Fletcher (19)
found positivity in two of 20 tumors, and Sub-
ranian et al. (20) in six of 10, but the latter group
did not ﬁnd any mutations in the KIT gene, in-
dicating that treatment with the tyrosine kinase
inhibitor imatinib is unlikely to have any effect.
Yet the marker may be helpful in the differential
diagnosis, as all the other tumors were negative
for CD117. The mainly negative reaction for
YKL-40issomewhatsurprising,becauseSj ¨ ogren
et al. (21), in their 10 cases, demonstrated over-
expression of the CHI3L1 gene (which codes for
YKL-40) by RT-PCR. However, they did not
perform immunohistochemical staining for the
protein. Positivity for bcl-2 has, to our knowl-
edge, not been described before, but it should be
worth investigating further, especially because
the over-expression of this apoptosis-preventing
protein is the target of several new strategies of
therapeutic intervention (22). Also, silencing of
the gene with small interfering RNA has recently
been shown to enhance radio-sensitivity in vitro
(23). The single poorly differentiated extra-
skeletal myxoid chondrosarcoma in our material
did not exhibit the same proﬁle. This might be
due to dedifferentiation, but another explana-
tion could be that this subtype is not truly re-
lated to the more differentiated, classical ones.
At least focal reactivity for smooth muscle
actin was found in all chondroblastomas and
a weak positivity was seen in two of the ﬁve
chondromyxoid ﬁbromas. In both entities, actin
positivity is interpreted as signifying myoﬁbro-
blastic differentiation (7, 8), which, in the chon-
dromyxoid ﬁbromas, is driven by the TGF-b1
pathway (8). The focal and weak reaction for
osteonectin also occurred primarily in myoﬁ-
broblast-like cells. Both benign tumors exhibited
a varying positivity for D2-40 and YKL-40,
mainly in areas with visible chondroid differ-
entiation. One of the chondromyxoid ﬁbromas
was strongly positive for calponin. This is in
contrast to the results of Romeo et al. (8), who
found no reaction for calponin in their 20 cases.
Osteonectin (also known as SPARC or BM-
40) is a secreted Ca-binding glycoprotein that
plays a role in the development of mesenchymal
cells, especially during the transformation of
chondroid tissue into bone, and recent interest in
this protein centers upon its role in response to
injury and tumor progression (24). Immuno-
histochemically, osteonectin is known to stain
osteosarcomas, but it also decorates chondro-
cytes, ﬁbroblasts and other non-neoplastic cell
types (6). The reaction pattern for osteonectin
was not informative, except for its absence in the
extraskeletal myxoid chondrosarcomas and its
tendency to be more intensely positive toward
the periphery of the chondroid nodules of chon-
drosarcomas and chondromyxoid ﬁbromas,
possibly reﬂecting the enchondral ossiﬁcation
process.
Mdm-2 has been reported to be a useful mar-
ker in liposarcomas (9), but is less well studied in
bone tumors. The p53/mdm2 pathway appears
to be involved in 40–50% of chondrosarcomas
and correlated with aggressive behavior (25) but
there is no agreement on the cut-off level for
positivity, and we did not ﬁnd any correlation
with histological grade, where eight of 25 (32%)
exhibited nuclear positivity for mdm-2 in 2–40%
of tumor cells.
In accordance with others (26), we did not ﬁnd
any expression of CD117 (c-kit) in any tumors
apart from the extraskeletal myxoid chon-
drosarcomas. The reported effect of imatinib in
the latter group may be mediated through auto-
or paracrine activation of PDGFRb, or other
pathways (10).
YKL-40, also known as human cartilage pro-
tein 39 or CHI3L1, is a secreted glycoprotein
whose precise function is unknown. It occurs
ubiquitously in normal adult human tissues, and
the staining intensity correlates with cellular ac-
tivity (metabolic or proliferative) (4, 26). During
fetal development, it acts as a growth factor for
chondrocytes and ﬁbroblasts, with differential
expression during the formation of bones and
joints (26), but YKL-40 is also expressed in some
cancers, and although no direct correlation be-
tween YKL-40 expression in tumor tissue and
corresponding serum/plasma levels has been de-
monstrated, elevated values of the latter are
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it should be kept in mind that elevated YKL-40
serum/plasma levels are also seen in non-malig-
nant diseases, e.g. bacterial infections, osteoar-
thritis or rheumatoid arthritis (26). This is the
ﬁrst study of YKL-40 expression in chondroid
tumors, and as normal chondrocytes stain for
this marker (4), it is hardly surprising that it
was also found in the chondroid tumors. The
two classical extraskeletal myxoid chon-
drosarcomas in this study were negative for
YKL-40, and the anaplastic one was only weak-
ly positive. These tumors are probably not his-
togenetically related to true chondrosarcomas.
Gene proﬁling has indicated neural/neuroendo-
crine differentiation (20, 21), and expression of
YKL-40/CHI3L1 has been demonstrated by
RT-PCR in 10 cases of extraskeletal myxoid
chondrosarcomas, but without performing im-
munohistochemical staining for the protein (20),
and the discrepancy may be caused by post-
translational modiﬁcation. As a routine im-
munohistochemical marker, YKL-40 is not
optimal, because it is too widespread, but it may
be of value in the postoperative follow-up of
patients with potentially malignant chondroid
tumors, and in the monitoring of patients with
multiple osteochondromas or enchondromas,
who have an increased risk of developing chon-
drosarcomas.
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